Invasive bronchopulmonary infection with Aspergillus species is major and increasing complication in immunocompromised patients. Over the last 30 years amphotericin B has remained the drug of choice for invasive aspergillosis despite its toxicity and low response rates of 30-55%. Resistance of the fungies to an inadequate concentration of the drug at the infection site might be responsible for the high mortality rate.
Invasive bronchopulmonary infection with Aspergillus species is major and increasing complication in immunocompromised patients. Over the last 30 years amphotericin B has remained the drug of choice for invasive aspergillosis despite its toxicity and low response rates of 30-55%. Resistance of the fungies to an inadequate concentration of the drug at the infection site might be responsible for the high mortality rate.
We report our experiences with local fiberoptic instillation in five patients (2 AML, 1 CML, 1 NHL, 1 ALL). Two patients suffered from aspergilloma and three from diffuse Aspergillus pneumonia. Response to systemic antimycotic treatment was insufficient. Therefore, amphotericine B (5-40 mg) or miconazole (25-200 mg) have been applicated between 3 and 9 times into the concerning segmental bronchi via fiberbronchoscope in wedge position in addition to the systemic therapy.
Side effects of instillation were transient cough and mild bronchospasm. In one case with aspergilloma a self-limited endobronchial bleeding after the second instillation occurred. The follow up showed improvement of the clinical performance and accelerated regression of pulmonary infiltrates without lethality and nearly complete resolution in three cases. The lung tissue received from later performed surgical resection of the right upper (destroyed) lobe of one patient showed no hyphae or other fungal elements.
In conclusion, the bronchoscopic instillation of antifungal agents can be used as an additional and well-tolerated option for the treatment of non-resolving Aspergillus infections of the lung, in particular if performance of surgical resection is impossible. Thus, further controlled studies are needed to prove the value of bronchoscopic instillation of antimycotics. In 17 patients (pts) with multiple myeloma (MM) treated with 2 consecutive cycles of high-dose therapy (HDT, melphalan 200 mg/m 2 ) followed by peripheral blood stem cell transplantation, the tumor load in bone marrow (BM) and in peripheral blood (PB) were analyzed. Samples were collected prior to 1st and 2nd, and after 2nd HDT. The median interval between 2nd HDT and sample collection was 132 days (range 94-330) . A quantitative PCR (qPCR) assay based on the method of limiting dilutions was employed S31 using allele specific oligonucleotide primers complementary to the CDR3 region of the immunoglobulin heavy chain gene. No differences in the tumor load in PB as well as BM were obvious between pts in PR and CR (15 in PR, 2 in CR, according to EBMT criteria). The median percentage of malignant cells in BM was 1.24% prior to 1st HDT, 0.18% between 1st and 2nd, and 0.069% post 2nd HDT. In PB, the median number of circulating malignant cells was 62 per ml prior to HDT, 2.3 per ml between 1st and 2nd HDT, and 4.9 per ml after 2nd HDT. While the 2nd HDT cycle led to a further decrease in the median tumor load of BM, this was not the case for PB. In 6 pts the tumor load in one of the BM-samples collected after start of HDT was found to be higher than in the BM-sample collected prior to HDT. Five of these 6 pts have developed progressive disease (at 10, 10, 12, 19 and 21 months after start of HDT). One patient remains in PR at 19 months. Among the remaining 11 pts, only 1 has relapsed at 19 months after 1st HDT (median follow-up in this subgroup 20 months, range 16-31). As pts with increased tumor load in BM after start of HDT seem to be at risk for earlier disease progression, they might benefit most from further consolidation therapies. The morphological diagnosis of plasmocytomas in the bone marrow is still based on arbitrarily defined percentages of plasmacells in smears or trephine biopsy sections. Since the classification of plasmocytoma by DURIE and SALMON a lot of further clinical and morphological parameters for assessment wether a plasmocytosis is reactive or neoplastic was proved.
P4: Monitoring of the Effect of Sequential High Dosis Therapy on the Tumor Burden in Patients with Multiple Myeloma by Means of PCR

P5: Grading of Plasmocytomas According AgNOR Pattern
Silver stained nucleolar organizer regions (AgNORs) are argyrophilic proteins associated with activated nucleolar organizer region genes showing the cells potency of activity and proliferation. They are now widely used as markers of diagnostic and prognostic value in tumor pathology. Almost all reported investigations in plasmocytoma infiltration of the bone marrow were dealt with trephine biopsy sections, although in hematological oncology the investigation of aspirates is a method which allows a fast and often definitive diagnosis.
We investigated the AgNOR-situation in routine obtained bone marrow aspirates from 49 patients with untreated plasmocytomas (21 females, 28 males, from 28 to 86 years of ages). In comparison we examined 20 patients with reactive plasmocytosis. First at all a staining technique for smears was proved on the basis of a modifyed histological method. The staining duration was 8 min. A counter-staining was performed with Giemsa for 1 min at 37°C. The conventional diagnosis was made in light microscope at 1000 fold magnification and oil immersion with Pappenheim's staining.
The plasmocytomas were divided into 3 grades of malignancy (G1-G3) on the basis of morphological criteria such as size and relation of cytoplasm and nucleus; presence, size and count of nucleoli; presence of mitosis and multinucleated cells. After AgNOR staining in each patient 100 plasmacells were examined and documented by video recording. The video sequences were analyzed by an automatic microscope image system (IBAS 2000 Video-plan, Kontron Eching/München, Germany). The measured AgNOR-associated parameters were count and area. In result the staining technique for smears allows a reproducible AgNOR demonstration both in fresh and archivated slides. Mean AgNOR-area and mean AgNOR-count are the most suitable parameters in standardized examination with automated microscope image analysis. Between reactive and neoplastic plasmocytosis there are differences in structure and distribution of AgNORs, even when only a small number of plasma cells was present. Concerning mean values of cell area, nuclear area and AgNOR-area, there was a linear increasing with progressive loss of differentiation. In consequence of high standard deviation of the individual measuring results there were no statistically significant differences. However, the use of F-test for groups of unequal size allows to find out significant differences between reactive plasmocytosis (G0) and plasmocytoma (G1 -G3) in the parameters cell and nuclear area. Whereas the mean AgNOR-area between reactive plasmo-cytosis (G0) and G1 has a difference with Յ5%, there was a difference between G0 and G2/G3 rsp. G0 and all plasmocytomas (G1-G3) with Յ1%. , cyclophosphamide 1300 mg/m 2 ) followed by filgrastim (Amgen-Roche) 10 g/kg. Optimal time for whole blood harvesting was on days 7-10, the best day being day 10. The yield: 8.9 ± 5.0 × 10 4 /kg CFU-GM and 1.82 ± 0.89 × 10 6 /kg CD34+ cells in 450 ml of whole blood. The blood was stored in standard blood collection S32 bags JMS (Japan Medical Supply) in the Tissue Bank, in a conventional refrigerator at +4°C and returned without other processing 2 days after chemotherapy without related complications. The use of whole blood is a very fascinating idea, but the hematological recovery was rather slower. Conclusion: A suitable method of whole blood priming and removing was developed in patients with breast cancer: it is more comfortable for the patients (out-patient regimen), technically simple and less expensive than the classic use of PBPC harvested by leukaphereses. (Summary: Peripheral blood progenitors mobilized and reinfused as unprocessed autologous whole blood after high-dose chemotherapy in patients with breast cancer).
P6
P7: Ex Vivo Expansion of Progenitor Cells After
Intensive Chemotherapy in Breast Cancer We studied the effect of stem cell factor (SCF), interleukin 3 (IL-3) and interleukin 11 (IL-11) on the proliferation of human CD34+/AC133+ progenitors isolated from leukapheresis products from chemotherapy plus granulocyte-colony-stimulating factor (G-CSF) -mobilized adult donors. MiniMACS AC133+ isolated cells contained a mean of 85% (80-90) AC133 cells. Enriched AC133 cells coexpressed CD34, CD71low and CD33 in 80%, 36.6% and 6.6% respectively. After a seven day ex vivo expansion in the presence of SCF+IL-3+IL-11, the expansion of cells increased 19 times. These cells expressed a mean of 12% CD34+, 74% CD71+ (23% CD71high) and 59% CD33+. This means that the number of CD34+ cells increased slightly, the number of CD33+ cells increased 100 times and the cells with a high density CD71high (23%) appeared. These cells represent the cells committed at erythroid differentiation. The increase in the number of CFU-GM with various combinations of cytokines SCF+IL-3+IL-11 will be discussed. The number of CFU-GM in culture after a seven-day ex vivo expansion in the presence of SCF+IL-3+IL-11 increased 45 times. ), or neonatal cord blood mononuclear cells (10 7 ) were intravenuously injected into sublethally irradiated non-obese diabetc/severe combined immunodeficiency (NOD/SCID) mice. Mice also received subcutaneous transplants of rat fibroblasts stably transfected with the human interleukin-3 gene. Immunohistochemical analysis of bone marrow cells 5 to 7 weeks after transplantation using human-specific antibodies revealed the establishment of a human lympho/myelopoiesis. In addition, von-Willebrand Factor(vWF)-positive cells (0.1 to 1 per cent) were detected. Cultures from the chimeric bone marrows were set up which, in addition to human hematopoietic cells, showed the formation of clusters or colonies of human HLA class-I-positive cells exhibiting rounded morphology and small nuclei. These cells regularly stained positive with anti-human monoclonal antibodies (mAb) directed to antigens expressed specifically on endothelial cells like vWF (clone F8/86) and CD31 (mab clones EN4, PalE). After prestimulation with rh-VEGF, they also bound an antibody specifically recognizing the human VEGF receptor-2, KDR. Control cultures established from non-transplanted mice were uniformly negative with all antibodies used. Organ slices from chimeric mice showed incorporation of human non-hematopoietic cells also into the spleen microarchitecture. When flowcytometrically sorted CD34 + CD38 low fractions from human adult peripheral blood had been grafted to the mice, human vWF-positive cells were missed in their bone marrows and spleens, while the human hematopoiesisrepopulating potential was quantitatively contained within these grafts indicating that the ECs may not be derived from a common progenitor with angio-hematopoietic potential present in human adult blood. Our data show that human endothelial (progenitor) cells contained in adult and neonatal human blood engraft in NOD/SCID mice. We investigated the Bone marrow (BM) processing with two separation protocols. First the manuell MNZ Software (n = 25) and second the automatically KMV Software (n = 12) of the Cobe Spectra. We compared different separation parameters, cell counts, CD34+-cells, and colony assays prior to and after separation. Bone marrow harvesting was performed during 1995-1998. The patients suffered from CML (n = 8), AML (n = 12), ALL (n = 5), Hodgkin's disease (n = 1), Cancer of the testis (n = 5); healthy donors (n = 6) S33 The median volume of bone marrow separated was 8536 ml (=7 times of marrow volume) in the MNZ-protocol and 7236 ml (=5.4 times of marrow volume) in the KMV-protocol).
Conclusion:
The KMV Software is a reproducible method of stem cell selection from the bone marrow. Because of the lower erythrocyte contamination of the bone marrow stem cell concentrate the KMV software could be used in cases of blood group major incompatibility in bone marrow transplantation, without any risk of hemolytic events for the recipient. The clinical importance of bone marrow processing is reduced. Today most of the stem cell transplantations are transplantations of peripheral blood stem cells. We investigated three different protocols of cooling rates used for cryopreservation of APBPC. Methods: First we used a computer assisted (I) defined cooling rate of 1°C to −40°C followed by 4°C/min to −100°C for Cryoperservation of APBPC. The second protocol (II) was a computer assisted rate of constantly -80°C (-4.5°C/min).Protocol I and II were performed on the Cryoson freezer. The third protocol (III) was performed on the Kryo 10 of Messer-Griesheim. The protocol used consisted of 9 rampes with different cooling, holding and heating rates beginning with holding of 0°C for 10 min, cooling of −0.8°C/min for 8 min, cooling of −50°C for 1 min, heating of 50°C for 0.5 min, holding of 2 min, cooling of −1°C for 15 min and cooling of −5°C until −120°C. Colony assays were performed before and after cryopreservation using Methocult H4443 in protocol I and II and Methocult H4444 in protocol III. CFU-GM recovery was estimated.
P10: Evaluation of Different Cooling Rates in
Results:
Parameter Protocol I n = 104 Protocol II n = 100 Protocol III n = 33 Abbreviations: pre, post = pre and post cryopreservation.
These findings suggest no that there is no significant difference of the three cooling procedures on CFU-GM and on viability as determined by dye exclusion. The median duration of hematological reconstitution (WBC 1 × 10 9 and platelet 50 Gpt/l without transfusion) was identical for the used protocols for WBC = 12 days, or for platelets = 15 days. Time required for cryopreservation was 57 min (I) versus 20 min (II) versus 63 min (III). Cooling rates lower than 5°C/min were tolerated well. 
P11: Comparison of Three CD34 -Selection Systems
Department of Hematology and Oncology of the Center of Internal Medicine of the University of Leipzig, Germany
We investigated cell counts, purity, CD34-recovery and CFU-GM-recovery of the CD34 -selection systems Ceprate SC (I, n = 20), Baxter Isolex 300i (II, n = 4) and Miltenyi Clini MACS (III, n = 17). The patients suffered from Multiple Myeloma (n = 10), Non Hodgkin Lymphoma (n = 14), Hodgkin's disease (n = 4) or solid cancers (n = 13) with bone marrow involvement.
Results:
Parameter Hospital Riesa, Germany
There is a tendency to dose intensification in induction and consolidation therapy in acute myelogenous leukemia in order to improve response rates. Dose intensification is currently investigated for the treatment of newly diagnosed patients with AML. This however results also in an increased bone marrow toxicity with subsequent insufficient mobilization and prolonged aplasia during high-dose therapy. We were interested to see the effect of high-dose Ara-C on the mobilization of stem cells. 15 patients (age: 18-59, 4 female, 11 male) from 6 centers underwent a mobilization therapy between July 1996 and September 1998. All patients got 1-2 courses of a HiDAC + idarubicin induction therapy (Arm A: Ara-C 2g/qm over 8 hrs, d 1, 3, 5, 7 and idarubicin 12 mg/qm, d 1, 2, 3; Arm B: Ara-C 1g/qm over 3 hrs q 12 h, d 1, 3, 5, 7 and idarubicin 12 mg/qm, d 1, 2, 3). Patients who achieved a CR received a consolidation treatment at the same dose. After a further consolidation course (Ara-C 2g/qm over 8 h d 1, 3, 5 and mitoxantron 10 mg/qm, d 1, 2) stem cells were mobilized with 2 × 5mg/kg G-CSF from day 7 till the end of the separation. A sufficient CD34
+ cells number was collected in 14 of 15 patients (lowest rate 1.9 × 10 6 CD34 + cells/kg). One patient with severe gramnegative sepsis could not show a sufficient increase of CD34 + cells. 12 of the 14 successful mobilized patients received an autologous stem cell transplantation, 9 patients are in CR till now (111-870 days), 1 patient died after myocardial infarction, 2 patients relapsed at day 50 and day 402 after transplantation. 2 patients relapsed before transplantation. After transplantation patients recovered granulocytes Ͼ500/l within median 13 days (range: 11-15). In both cases, the explanation is pregeneration of Agspecific immunocompetent Th cells, more precisely Th2 cells ("inducer suppressor cells"), which predetermine the Th2 profile of the CD4 positive and the Ts function of the CD8 positive Ag-specific precursor cells ("transducer auppressor cells"). Whether this Th2 commitment is initiated by the type 2 cytokines in the microenvironment of precursor/naive T cells which are dominant if competing with the type 1 cytokines or is mediated by microphages which had been reprogrammed to suppressor monocytes by Th2 cells, remains to be elucidated.
P21: Can Cytotoxic T Cells (CTLs) and Suppressor T cells (Ts
As it is known that the Th1 commitment requires IL-12 S35 presence and that IL-10 downregulates the Th1 subset and upregulates the Th2 subset via IL-12 inhibition, we tried to prevent the early IL-10 secretion by the APCs via blockade of Gs-coupled receptors, e.g. A2/P1-purinergic receptor, ␤-AR, PGE2-R, H2-R, S2-R and/or D1-R. To test the working hypothesis that the same PBL suspension can contain both cytoxic T cells (CTLs) and suppressor T cells (Ts), more precisely Th2 cells, "educating" precursor CD4 positive cells to become Th2 and CD8 + cells to differentiate into Ts cells, we tested a series of test substances, including agonists and antagonists of immunologic and non-immunologic receptors and their subtypes, further different stimulators and inhibitors of membrane associated and intracellular enzymes, such as protein kinases PKC, PKG, PKA, as well as different modulators of cationic channels (Ca 2+ -and K + -channels) and of various ion symporters and antiporters.
We tested the influence of test substances both (a) on resting, mature immunocytes and (b) on proliferating PBLs (alloactivated precursors in the MLC and mitogen-activated precursors in the PHA proliferation test), and (c) the impact of resting cells, pretreated by test substances and their combinations, on non-primed T cells (in the absence of test substances).
The cytotoxic effect was measured in a "long-term CML/LMC test" and partially in a "short-term CML/LMC test".
Our results show that the high cytolytic activity of premanipulated PBLs doesn't exclude a strong immunosuppressive effect on naive cells and their precursors. This phenomenon is bsed on the cogeneration of mature, antigen-specific Th2 cells in the PBL suspension which -when co-cultured with fresh non-primed T cells of the same person -leads to the Th2/Ts-commitment of maturing T cells.
P22: Oligoclonal Stimulation of Alloreactive T Cells
Results in a Strong Non-Specific Immunosuppression Hyperactivation or persistent immunostimulation result in immunosuppression. Even in LAS/ARC/AIDS which is characterized by a profound immunideficiency, there is a hyperactivation rather than hypoactivation of immunocompetent cells such as monocytes/macrophages and T cells which can be deduced from some phenotypiocal cell markers and/or secretory products of overstimulated immunocytes; some of these secretory products, such as neopterin/biopterin, soluble CD8 structure, ␤2 microglobulin and lysozyme serve as early markers of disease progress, e.g. from the LAS over the ARC to the AIDS stage. When we measured cell activity in the MLC test, we were first suprised to observe a clear immune suppression following the coincubation of donor and recipient PBLs in all 3 systems (a) the "one-way-MLC" (b) the "two-way-MLC", and (c) in the absence of any pretreatment of either donor or recipient PBLs, when compared with the activity of donor and recipient PBLs, incubated under the same experimental conditions in separate cultures.
One explanation is the overproduction of cytokines by the oligoclonal activation of allogeneic (including bystander) T cells,representing up to 2-3%, in extreme cases even up to 10% of all T cells. Another interpretation is the immunosuppression, caused by some metabolic products, such as adenosine, epinephrine/norepinephrine, PGE2, histamine, serotonin, dopamine and possibly cortisole, most of them acting via non-immunological receptors. As some of these agents are either instable (e.g. PGE2 as lipid peroxide) or taken up in extremely short time (10-1000 ms), such as adenosine, we in addition tested the immunsuppression during the donor: recipient co-culture in dependence of the average distance between immunocompetent cells by varying (a) the number and (b) the conditions of precentrifugation of donor and recipient PBLs (g number and time of centrifugation).
By the systematic study of different blockers of cAMPincreasing Gs-coupled receptors as well as by the analysis of various (immuno)modulators, preventing anergy and cell hyperpolarization, we hope to obtain an instrument for the circumvention of the fatal immunosuppression which is associated with the common clinical situation of hyper-not hypoactivation of immunocompetent cells.
Our experimental setting permits the quantitative evaluation of known and unknown factors which are responsible for the immune suppression, resulting from the hyperactivated state of immunocytes.
P23: Searching for the Differences Between the Th1
(Tc) and Th2 (Ts) Subset According to our hypothesis, the Th1 and Th2 cells on one side and the Tc and Ts cells on the other side represent the identical cell type in two functional states whose commitment is not irreversible, so that the subsets can be, dependent on the nature and intensity of the microenvironment signals, mutually interconverted.
To test the hypothesis that the Th2 and Ts cells, secreting the type 2 cytokines, differ from Th1 and Tc cells which synthetize type 1 lymphokines primarily in the activation of the PC-dependent PLC, as opposed to the activation of the PI-dependent PLC in the Th1 and Tc-subset, we compared the lymphocyte activity in the presence and absence of different Ca antagonists (Ca channel blockers), using S36 standard laboratory techniques (MLC,CML/LMC and PHA-proliferation assay).
Since only the PI dependent PLC mobilizes intracellular Ca ++ , the activation of both, the Th2 and the Ts subset seems to depend in a critical way on the influx of the extracellular Ca ++ ,which can be inhibited by Ca antagonists. Our results show that all tested Ca antagonists (nifedipine/nicardipine, verapamil and dilthiazem) significantly increased the activity of immunocompetent cells, the most efficient being nicardipine which showed even at extremely low concentration of 1.10 −12 M a 52% (!) overall PBL stimulation (in the PHA-proliferation assay). We interprete this observation as deblocking of the immunosuppressive T cell subsets, responsible for the generalized downregulation of the immunocyte activity.
We chose the highly sensitive AA(adjuvant arthritis)-model in rats (Lewis and WKY-strain) for measurement of the cell activity in vivo. Whereas the classical Ca antagonists (nifedipine) led to a significantly increased reactivity of autoaggressive T cells in AA-induced animals, the Ca overload blocker cinnarizine inhibited the AA-establishment.
A further difference between Th1/Tc and Th2/Ts subsets is related to the ROS:RNS equilibrium.
Ligation of G 0 -coupled receptors activates the PI-dependent PLC, resulting in the generation of two second messengers, the ER-Ca mobilizing IP3 and the PKC stimulating DAG. The Ca ++ -elevation is involved in the NO generation by cNOS via stimulation of the -Ca
